Clinical Trial Update: Efficacy of Rifaximin in Preventing Campylobacteriosis [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on rifaximin for prevention of Campylobacteriosis shows completed Phase 2/3 study results; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diarrhea
• Dysentery
• Enteric Campylobacteriosis

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Johns Hopkins Bloomberg School of Public Health | Conditions: Dysentery, Diarrhea | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2018-11-20